Q1 2023 Results
Company overview
Innovation: Pipeline overview
Financial review
Financial performance
Conclusions
Appendix
Innovation: Clinical trials
References
Abbreviations
GROWTH
ZolgensmaⓇ sales declined mainly due to pricing dynamics
Maintaining leading share in US in <2 years¹; new data demonstrates durability of effect up to 7.5 years 2,3
Sales evolution
USD m, % cc
zolgensma®
Ex-US
US
363
-14%
309
250
200
Q1 sales dynamics driven by one-time reimbursement events in PY
and ongoing pricing mix dynamics
Treatment mainly in incident patients; maintaining >90% share in US1
Continued geographic expansion2 and access expansion to label
OAV101 IT development on track (Ph 3 STEER and
STRENGTH trials)
Sustained durability up to 7.5 years (data at MDA)³: 25/25 children
treated prior to SMA symptom onset achieved walking alone 4,5
113
Q1 2022
See page 94 for references 1-5.
109
Q1 2023
SMA spinal muscular atrophy. IT intrathecal. MDA-muscular dystrophy association.
41 Investor Relations | Q1 2023 Results
NOVARTIS | Reimagining MedicineView entire presentation